Polpharma API characteristics:
- Stable amorphous form
- Laboratory validation samples with quality above 98,5%
- Well characterized disulfide (S-S) bonds positioning
- Ion free content
- Technical support available on request - dedicated ‘peptide team’ to answer your questions
Linaclotide is an anti-constipation agent.
Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
It is formulated as capsule and tablet for oral route of administration.
Mechanism of action:
Linaclotide is an agonist of guanylate cyclase type-C (GC-C), a receptor found on epithelial cells lining the intestine. Linaclotide promotes activation of the CFTR chloride channel. Activation of intestinal GC-C induces secretion of fluid, sodium and bicarbonate in the intestinal lumen. The activation of GC-C leads to increases in cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit. In addition, both linaclotide and cGMP demonstrated anti-nociceptive effects in several preclinical models of visceral pain.